Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$30 Mln
P/E Ratio
--
P/B Ratio
3.32
Industry P/E
28.11
Debt to Equity
0
ROE
-1.46 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-26.64 Mln
EBITDA
$-39.48 Mln
Net Profit
$-36.12 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
| -44.29 | -31.98 | -31.58 | -50.21 | -25.24 | -32.77 | -11.16 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Lexaria Bioscience (LEXX)
| 67.29 | -49.19 | -38.96 | -46.12 | -34.82 | -58.87 | -44.79 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 29.44 | 823.22 | -- | -48.88 | |
| 0.49 | 490.76 | -- | -- |
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich... triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. Address: 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7 Read more
Chairman & CEO
Mr. Christopher A. Bunka
Chairman & CEO
Mr. Christopher A. Bunka
Headquarters
Kelowna, BC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Lexaria Bioscience Corp (LEXX) stood at $ 10 Mln as on 28-Feb-25
The share price of Lexaria Bioscience Corp (LEXX) is $1.17 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Lexaria Bioscience Corp (LEXX) has given a return of -25.24% in the last 3 years.
Lexaria Bioscience Corp (LEXX) has a market capitalisation of $ 30 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Lexaria Bioscience Corp (LEXX) is 3.32 times as on 28-Apr-2025, a 34% discount to its peers’ median range of 5.04 times.
Since, TTM earnings of Lexaria Bioscience Corp (LEXX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lexaria Bioscience Corp (LEXX) and enter the required number of quantities and click on buy to purchase the shares of Lexaria Bioscience Corp (LEXX).
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. Address: 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7
The CEO & director of Mr. Christopher A. Bunka. is Lexaria Bioscience Corp (LEXX), and CFO & Sr. VP is Mr. Christopher A. Bunka.
There is no promoter pledging in Lexaria Bioscience Corp (LEXX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
81
|
|
|
46
|
|
|
81
|
|
|
46
|
| Lexaria Bioscience Corp. (LEXX) | Ratios |
|---|---|
|
Return on equity(%)
|
-123.47
|
|
Operating margin(%)
|
-748.82
|
|
Net Margin(%)
|
-1784.18
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Lexaria Bioscience Corp (LEXX) was $0 Mln.
$-0.05
(
